Quick Answer
Kairos Pharma, LTD. reported Research And Development Expense of $2.14 million for the year ending 2025.
- Kairos Pharma, LTD. showed an increase of +415.7% in Research And Development Expense from 2024 to 2025.
- This data is from Kairos Pharma, LTD.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2023 to 2025), Kairos Pharma, LTD.'s Research And Development Expense has grown by 2,503.7%.
- Historical annual values: Fiscal year 2025: $2.14 million | Fiscal year 2024: $414.0 thousand | Fiscal year 2023: $82.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: